**Warsaw Appeals €1.3bn Covid Bill Linked to Controversial Vaccine Deal**
Poland has formally appealed a Belgian court ruling that mandates the country to pay approximately €1.3 billion for Covid-19 vaccine doses it opted not to accept under a contentious European Union vaccine procurement agreement. This legal battle has its roots in the multibillion-euro contracts negotiated by Ursula von der Leyen, the President of the European Commission, with pharmaceutical companies Pfizer and BioNTech during the height of the pandemic.
The situation has drawn significant attention, particularly due to the so-called ‘Pfizergate’ scandal, which has raised questions about the transparency of the vaccine procurement process. The Polish Health Ministry announced on Monday that it has filed the appeal and requested a suspension of the enforcement of the court's ruling while the case is reviewed. The ministry contended that the lower court did not adequately consider all pertinent factual and legal circumstances, although it did not provide further specifics on its arguments.
The legal dispute began when Pfizer initiated a lawsuit against Poland in 2023 after the country halted the acceptance of vaccine deliveries. Pfizer argued that Poland's decision was based on falling demand for vaccines, an oversupply situation, and the economic repercussions of the ongoing conflict in Ukraine, which the company classified as force majeure.
In April, the Brussels court ruled in favor of Pfizer, stating that Poland must receive approximately 64 million doses and fulfill its financial obligations, which include the €1.3 billion payment along with interest and legal fees. Pfizer has defended the court's decision, asserting that it underscores the significance of contractual commitments that were crucial for the EU's pandemic response. The company also highlighted that it had exhibited considerable flexibility towards EU member states before resorting to legal action.
Ursula von der Leyen's role in the vaccine negotiations has come under scrutiny, with critics accusing her of withholding key details regarding the discussions with Pfizer and AstraZeneca. One of the major points of contention has been her refusal to disclose or retain text messages exchanged with Pfizer's CEO, Albert Bourla, during the negotiations. This controversy led to a no-confidence motion in the European Parliament last year, which von der Leyen ultimately survived.
As the appeal process unfolds, the implications of this case may extend beyond Poland, potentially affecting the broader EU vaccine procurement strategy and the relationship between member states and pharmaceutical companies. The outcome could also influence future negotiations and contracts related to public health emergencies within the EU framework.
The Polish government’s decision to challenge the ruling reflects ongoing tensions within the EU regarding vaccine distribution and the management of public health resources during the pandemic. With the appeal now in motion, it remains to be seen how the Belgian courts will respond and what this will mean for Poland's financial obligations and its stance on vaccine procurement in the future.